Page 39 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

Moderator

胡琮輝 Professor Tsung-Hui Hu
E-mail: dr.hu@msa.hinet.net

Professor, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Professor, Medical School, Chang Gung University, Taoyung, Taiwan.

Biography

Dr. Tsung-Hu Hu earned his M d from t China M University and Ph.D degree at

th of Clinica Sciences from Chang Gung University. He then

completed his clinical training in internal medicine at Chang Gung Memorial Hospital

(Linkou) and gastroenterology at the Chang Gung Memorial Hospital, Kaohsiung, Taiwan. Currently,
he is the professor of Chang Gung Memorial Hospital and University since 2012.

Dr. Hu initially focused on the research of molecular biology of hepatocellular

carcinoma (HCC), as well as gastrointestinal stromal tumors (GIST). He was one the pioneers

on the study of PTEN-AKT signal pathway of liver cancers in Taiwan. He was also one of

the pioneers studying molecular basis of GIST in Taiwan. Both of the pathways are widely

used in clinical practice nowadays.

Currently, Dr. Hu is interested in the treatment of hepatitis B and C, as well as antiviral

therapies after liver transplantation. His efforts led to the establishment of predictive models

HCC development after antiviral therapies of hepatitis B and C in Taiwan, especially for

patients who were already with sustained virological response. In addition, he was also one of the

pioneers to discover the impact on kidney function from antiviral therapies, such as telbivudine,

entecavir and tenofovir. Dr. Hu also participates in a novel program of

community based HCC screening and micro-elimination of hepatitis C in Changhua county

of Taiwan, which is still ongoing. HCV elimination in special populations such as patients

with dialysis, HIV co-infection, incarceration, and PWIDs receiving opioid substitution therapy
were completed.